Sivelestat (Selective Neutrophil Elastase Inhibitor) Improves the Mortality Rate of Sepsis Associated With Both Acute Respiratory Distress Syndrome and Disseminated Intravascular Coagulation Patients

Hayakawa, Mineji; Katabami, Kenichi; Wada, Takeshi; Sugano, Masahiro; Hoshino, Hirokatsu; Sawamura, Atsushi; Gando, Satoshi

Sivelestat (Selective Neutrophil Elastase Inhibitor) Improves the Mortality Rate of Sepsis Associated With Both Acute Respiratory Distress Syndrome and Disseminated Intravascular Coagulation Patients

Hayakawa, Mineji; Katabami, Kenichi; Wada, Takeshi et al.

Shock, 2010, 33(1), 14-18

Permalink : https://hdl.handle.net/2115/44581

このアイテムのアクセス数:1,784件（2026-03-05 15:13 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Hayakawa	pdf	96.7 KB	2,143

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/44581
タイトル	Sivelestat (Selective Neutrophil Elastase Inhibitor) Improves the Mortality Rate of Sepsis Associated With Both Acute Respiratory Distress Syndrome and Disseminated Intravascular Coagulation Patients
著者	Hayakawa, Mineji ; Katabami, Kenichi ; Wada, Takeshi ; Sugano, Masahiro ; Hoshino, Hirokatsu ; Sawamura, Atsushi ; Gando, Satoshi
著者名 Hayakawa, Mineji
著者名 Katabami, Kenichi
著者名 Wada, Takeshi
著者名 Sugano, Masahiro
著者名 Hoshino, Hirokatsu
著者名 Sawamura, Atsushi
著者名 Gando, Satoshi
言語	英語
キーワード	Acute lung injury
	Critically ill patients
	Protease
	Leukocyte
	Endothelial cell
発行日	2010-01
出版者	Lippincott Williams & Wilkins
収録物名	Shock
巻(号)	33(1)
ページ	14-18
抄録	Introduction: Neutrophil elastase plays an important role in the development of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC) in sepsis. Sivelestat is a selective neutrophil elastase inhibitor. It is possible that sivelestat improves the outcome of septic patients associated with ARDS and DIC. Methods: A retrospective data analysis of septic patients associated with ARDS and DIC was conducted to investigate the effects of sivelestat. Observational period was 5days after admission to ICU. Results: The study included 167 septic patients associated with ARDS and DIC. Control group included 133 patients without sivelestat and sivelestat group included 34 patients started to de administered sivelestat on the admission to ICU. The lung injury scores and Pa_[O2]/Fi_[O2] ratio of the sivelestat group were significantly more severe than those of the control group from day 1 to day 4. On day 5, the lung injury score and Pa_[O2]/Fi_[O2] ratio of the sivelestat group improved to the same levels of those of the control group. The DIC score of sivelestat group improved on day 3 in comparison to day 1, those of control group remained unchanged until day 4. The length of ICU stay of the sivelestat group was significantly shorter than that of the control group. A stepwise multiple logistic-regression analysis showed the sivelestat administration to be an independent predictor of survival of the septic patients associated with both ARDS and DIC. Conclusions: The length of ICU stay of the sivelestat group was significantly shorter than that of the control group. In addition, sivelestat administration was found to be an independent predictor of survival of those patients.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a non-final version of an article published in final form in Shock:Jan. 2010, 33(1), pp.14-18.
PISSN	1073-2322
関連情報	PMID 19487982
関連情報	URI http://www.shockjournal.org/pt/re/shock/
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1097/SHK.0b013e3181aa95c4